Division of Hematology-Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Oncologist. 2017 Oct;22(10):1238-1249. doi: 10.1634/theoncologist.2017-0174. Epub 2017 Jul 11.
BACKGROUND: In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6-week, home-based, self-directed walking program on the commonly reported side effect of AI-associated arthralgia (AIAA). MATERIALS AND METHODS: In this phase II trial, consented BC patients were randomized to walking Intervention ( = 31) or Wait List Control (WLC; = 31). Eligibility criteria included: stage 0-III BC, on AI for at least 4 weeks, ≥3 on a 5-point scale inquiring about joint symptom intensity "at its worst," and exercising ≤150 minutes per week. Outcomes were self-reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention-to-treat basis to assess intervention impact at 6 weeks (postintervention) and at 6-months follow-up. Adjusted means were calculated to assess differences in two groups. RESULTS: In our final sample ( = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6-months follow-up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. CONCLUSION: This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. IMPLICATIONS FOR PRACTICE: Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often experience the side effect of AI-associated arthralgia (AIAA). This study investigates the impact of a 6-week, home-based, self-directed walking program in the management of AIAA. Compared with Wait List Control, women in the Intervention group reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA.
背景:在被诊断患有乳腺癌(BC)的绝经后妇女中,大多数 BC 肿瘤为激素受体阳性,指南建议辅助内分泌治疗,包括芳香酶抑制剂(AI)。本研究调查了为期 6 周的、基于家庭的、自我指导的步行计划对 AI 相关关节痛(AIAA)这一常见不良反应的影响。
材料与方法:在这项 II 期试验中,同意参加的 BC 患者被随机分为步行干预组(n=31)和等待名单对照组(WLC;n=31)。入选标准包括:0-III 期 BC,AI 治疗至少 4 周,在询问“最严重时”关节症状强度的 5 分制中得分为 3 分或以上,每周运动时间≤150 分钟。结局指标为关节症状和心理社会测量。对干预组和 WLC 组进行意向治疗分析,以评估 6 周(干预后)和 6 个月随访时的干预效果。为评估两组间的差异,计算了调整后的均值。
结果:在我们的最终样本(n=62)中,平均年龄为 64 岁,74%为白人,63%的体重指数为 30 或更高。在干预后,干预组参与者每周的步行分钟数显著增加,僵硬程度减轻,日常生活活动(ADL)困难减少,管理关节症状时的无助感减轻。在 6 个月随访时(干预和 WLC 的步行后阶段),每周的步行分钟数显著减少;然而,僵硬和 ADL 困难的改善仍得以维持。
结论:本研究为越来越多的证据基础增添了内容,表明运动是 AIAA 管理中替代或辅助药物治疗的一种安全选择。
实践意义:接受芳香酶抑制剂(AI)辅助内分泌治疗的乳腺癌幸存者常出现 AI 相关关节痛(AIAA)的副作用。本研究调查了为期 6 周的、基于家庭的、自我指导的步行计划在 AIAA 管理中的作用。与等待名单对照组相比,干预组女性每周的步行分钟数显著增加,僵硬程度减轻,ADL 困难减少,管理关节症状时的无助感减轻。本研究为越来越多的证据基础增添了内容,表明运动是 AIAA 管理中替代或辅助药物治疗的一种安全选择。
Jpn J Clin Oncol. 2025-1-8
Rheumatol Adv Pract. 2024-4-10
Eur J Cancer Care (Engl). 2014-7